Business Context and Reporting Period
This Form 8-K filing by Ingevity Corp (NGVT) was submitted on March 19, 2021, reporting events occurring on that date. The filing focuses on executive leadership changes, specifically the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report regarding personnel and compensation rather than a financial performance report.
Material Changes
- Executive Appointment: The Board appointed Mary Dean Hall as Executive Vice President and Chief Financial Officer, effective April 19, 2021.
- Interim Role: John C. Fortson, President and CEO, currently serves as interim CFO.
- Compensation Structure: Ms. Hall's compensation package includes a $500,000 annual base salary, short-term and long-term incentive plans, and significant one-time equity grants to replace forfeited compensation from her previous employer.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. It details standard severance and change-in-control benefits comparable to other executive officers, including multipliers of 2x and 1x for specific termination scenarios. No specific risks or contingencies related to operations are disclosed in this document.
Investor Verification Checklist
- Verify the effective date of Mary Dean Hall's appointment (April 19, 2021).
- Review the total value of one-time equity grants ($1,633,113 in grant date value) intended to replace forfeited compensation from Quaker Chemical Corporation.
- Confirm the terms of the Short-Term Incentive Plan (STIP) target (70% of base salary) and Long-Term Incentive Plan (LTIP) target (150% of base salary).
- Check the referenced press release (Exhibit 99.1) for additional context on the leadership transition.